Oxford Gene Technology Ltd. Release: RNA-Seq Webinar Describes Novel Insights Into The Control Of Gene Expression
7/2/2014 9:10:38 AM
Oxford, UK – 2 July 2014. Oxford Gene Technology (OGT), The Molecular Genetics Company, has made the latest in its series of educational webinars available to watch online at www.ogt.com/webinars. In the webinar entitled “Developing new insights into gene expression using RNA-Seq”, Dr Christopher Jones, Research Fellow at the Brighton and Sussex Medical School (BSMS), UK, presents novel findings from a recent RNA-Seq project performed by OGT.
RNA-Seq is proving to be a valuable tool for enabling researchers to gain greater insight into changes in gene expression during disease initiation, progression, treatment and the development of drug resistance. In his presentation, Dr Jones discusses his use of Drosophila melanogaster as a model organism for investigating the control of gene expression via mRNA degradation and explores a range of interesting findings from the work that OGT carried out via its Genefficiency™ RNA-Seq Service. These have given new insights into the number of upregulated and downregulated genes in different null mutants and the degree to which expression of these genes changes. This was made easier by OGT’s interactive reporting, which enables simple and rapid understanding of RNA-Seq data without the need for in-house bioinformatics support.
View the webinar “Developing new insights into gene expression using RNA-Seq”, here.
For more information on OGT’s products and services, please visit www.ogt.com.
For further information, please contact:
Oxford Gene Technology, Begbroke Science Park, Begbroke Hill, Woodstock Road, Begbroke, Oxfordshire, OX5 1PF, U.K.
T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684
E: email@example.com ; W: www.ogt.com ; Twitter: @OxfordGeneTech
About Oxford Gene Technology
Oxford Gene Technology (OGT) provides world-class genetics research solutions to leading clinical and academic research institutions. Founded by Professor Sir Edwin Southern, and with customers in over 60 countries worldwide, OGT has a strong reputation and increasing share in the large and growing genomic medicine market. The Company’s Cytocell®, CytoSure™, SureSeq™ and Genefficiency™ range of fluorescence in situ hybridisation (FISH), microarray and next generation sequencing (NGS) products and services deliver high-quality genetic analysis, enabling accurate identification and confirmation of the causative variation underlying genetic disease.
For more information on the Company, please visit our website at www.ogt.com
CytoSure™ and Genefficiency™ NGS browser/report: For Research Use Only; Not for Use in Diagnostic Procedures
CytoSure: This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.
Help employers find you! Check out all the jobs and post your resume.
comments powered by